- $8.12bn
- $7.95bn
- $2.43bn
- 94
- 25
- 95
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.46 | ||
| PEG Ratio (f) | 1.63 | ||
| EPS Growth (f) | 15.12% | ||
| Dividend Yield (f) | 0.37% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.87 | ||
| Price to Tang. Book | 19.12 | ||
| Price to Free Cashflow | 25.78 | ||
| Price to Sales | 3.26 | ||
| EV to EBITDA | 17.16 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 27.08% | ||
| Return on Equity | 26.11% | ||
| Operating Margin | 15.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,079.58 | 2,139.26 | 2,134.96 | 2,264.42 | 2,431.29 | 2,632.98 | 2,795.85 | 4.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +29.54 | +0.92 | -6.26 | +8.52 | +13.9 | +18.72 | +8.61 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chemed Corporation is engaged in purchasing, operating, and divesting subsidiaries in diverse business activities. The Company's segment includes VITAS and the Roto-Rooter. The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. It provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. The Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Roto-Rooter services are provided through a network of Company-owned branches, independent contractors and franchisees. The Company's water restoration services involve the remediation of water and humidity after a flood and are provided to both commercial and residential customers.
Directors
- George Walsh NEC (75)
- Kevin McNamara PRE (67)
- David Williams CFO (60)
- Spencer Lee EVP (65)
- Nicholas Westfall EVP
- Michael Witzeman VPR (50)
- Brian Judkins VPR (40)
- Thomas Hutton DRC (70)
- Ron DeLyons IND (59)
- Joel Gemunder IND (81)
- Patrick Grace IND (65)
- Christopher Heaney IND (67)
- Andrea Lindell IND (77)
- Thomas Rice IND (71)
- Donald Saunders IND (76)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 2nd, 1970
- Public Since
- May 27th, 1971
- No. of Shareholders
- 1,156
- No. of Employees
- 15,695
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 14,614,676
- Address
- 255 E. Fifth Street,, Suite 2600,, CINCINNATI, 45202
- Web
- https://www.chemed.com/
- Phone
- +1 5137626690
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CHE
Chemed Corp Annual Shareholders Meeting
Q2 2025 Chemed Corp Earnings Release
Q3 2025 Chemed Corp Earnings Release
Similar to CHE
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health Partners
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
What is the Chemed share price?
As of Today at 19:53 UTC, shares in Chemed are trading at $555.74. This share price information is delayed by 15 minutes.
How has the Chemed share price performed this year?
Shares in Chemed last closed at $555.74 and the price had moved by -3.07% over the past 365 days. In terms of relative price strength the Chemed share price has underperformed the S&P500 Index by -10.53% over the past year.
What are the analyst and broker recommendations for Chemed?
The overall consensus recommendation for Chemed is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Chemed dividend yield?
The Chemed dividend yield is 0.34% based on the trailing twelve month period.
Does Chemed pay a dividend?
Last year, Chemed paid a total dividend of $1.90, and it currently has a trailing dividend yield of 0.34%. We do not have any data on when Chemed is to next pay dividends.
When does Chemed next pay dividends?
We do not have data on when Chemed is to next pay dividends. The historic dividend yield on Chemed shares is currently 0.34%.
How do I buy Chemed shares?
To buy shares in Chemed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chemed?
As of the previous close price of $555.74, shares in Chemed had a market capitalisation of $8.12bn.
Where are Chemed shares listed?
Here are the trading details for Chemed:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CHE
What kind of share is Chemed?
Based on an overall assessment of its quality, value and momentum Chemed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chemed share price forecast for 2025?
The analyst consensus target price for shares in Chemed is $675.00. That is 21.46% above the last closing price of $555.74.
Analysts covering Chemed currently have a consensus Earnings Per Share (EPS) forecast of $25.21 for the next financial year.
Find out moreWhat is the trend in the Chemed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chemed. Over the past six months, its share price has underperformed the S&P500 Index by -2.86%.
As of the last closing price of $555.74, shares in Chemed were trading -2.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chemed PE Ratio?
The Chemed PE ratio based on its reported earnings over the past 12 months is 21.46. The shares last closed at $555.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chemed?
Chemed's management team is headed by:
- George Walsh - NEC
- Kevin McNamara - PRE
- David Williams - CFO
- Spencer Lee - EVP
- Nicholas Westfall - EVP
- Michael Witzeman - VPR
- Brian Judkins - VPR
- Thomas Hutton - DRC
- Ron DeLyons - IND
- Joel Gemunder - IND
- Patrick Grace - IND
- Christopher Heaney - IND
- Andrea Lindell - IND
- Thomas Rice - IND
- Donald Saunders - IND